Sonrotoclax

Sonrotoclax, sold under the brand name Beqalzi, is a medication used for the treatment of hematologic malignancies, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).^[1] It is a potent and selective BCL2 inhibitor that can overcome resistance associated with BCL2 mutations, such as the G101V variant, which limits the effectiveness of first-generation inhibitors like venetoclax.^[2]

Sonrotoclax is indicated for the treatment of adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor.^[3]

Sonrotoclax is contraindicated with strong CYP3A inhibitors at initiation and ramp-up phase due to potential increased risk of Tumor lysis syndrome.^[3]

Sonrotoclax was approved by the FDA for medical use in the United States in May 2026.^[3] Sonrotoclax is also approved in China for mantle cell lymphoma, along with CLL/SLL.^[3]

Sonrotoclax also has a fast track designation by the FDA for Waldenström macroglobulinemia. It additionally has an orphan drug designation by the FDA for Waldenström macroglobulinemia, multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes.^[3]

Sonrotoclax is the international nonproprietary name.^[4]

Sonrotoclax is sold under the brand name Beqalzi.^[3]

0.00 (0 votes) Original source: https://en.wikipedia.org/wiki/Sonrotoclax. Read more